表紙:表皮水疱症治療薬の世界市場:2019年~2023年
市場調査レポート
商品コード
781917

表皮水疱症治療薬の世界市場:2019年~2023年

Global Epidermolysis Bullosa Therapeutics Market 2019-2023

出版日: | 発行: TechNavio (Infiniti Research Ltd.) | ページ情報: 英文 128 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.03円
表皮水疱症治療薬の世界市場:2019年~2023年
出版日: 2019年01月17日
発行: TechNavio (Infiniti Research Ltd.)
ページ情報: 英文 128 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 目次
概要

過去数十年にわたって行われた重要な研究活動にもかかわらず、副作用のほとんどない表皮水疱症の有望な治療薬は、まだ開発されていなません。従って、様々な政府機関および民間機関が、表皮水疱症の治療に現在利用可能な薬よりも優れた安全性と有効性を示すことができる有望な治療薬の開発に関する研究を推進するための資金を発表しています。欧州における表皮水疱症の研究に対する資金も増加しています。そのような資金および資金援助は、表皮水疱症の治療のための新規治療薬の開発に役立っています。 Technavioのアナリストは、世界の表皮水疱症治療薬市場が2023年までに約5%のCAGRで成長すると予測しています。

当レポートでは、世界の表皮水疱症治療薬市場について調査分析し、市場規模と成長率、市場動向、市場促進要因・課題、市場機会について検証するほか、主要ベンダーなどについて、体系的な情報を提供しています。

目次

第1章 エグゼクティブサマリー

第2章 レポートの範囲

  • イントロダクション1
  • イントロダクション2
  • 米ドルの通貨換算レート

第3章 市場状況

  • 市場エコシステム
  • 市場の特徴
  • 市場セグメンテーション分析

第4章 市場規模

  • 市場の定義
  • 市場規模(2018年)
  • 市場規模および予測(2018年~2023年)

第5章 ファイブフォース分析

  • バイヤーの交渉力
  • サプライヤーの交渉力
  • 新規参入の脅威
  • 代替品の脅威
  • 競争相手の脅威
  • 市況

第6章 市場セグメンテーション:製品別

  • 市場セグメンテーション:製品別
  • 製品別比較:市場規模および予測(2018年~2023年)
  • 抗生物質
  • 鎮痛薬
  • その他の治療薬
  • 市場機会:製品別

第7章 顧客情勢

第8章 地域情勢

  • 地域別セグメンテーション
  • 地域別比較:市場規模および予測(2018年~2023年)
  • 北米
  • 欧州
  • アジア
  • その他の地域
  • 主要国
  • 市場機会

第9章 成長要因と課題

  • 市場成長要因
  • 市場の課題

第10章 市場動向

第11章 ベンダー情勢

  • 概要
  • 創造的破壊の状況
  • 競合シナリオ

第12章 ベンダー分析

  • 対象ベンダー
  • ベンダー分類
  • ベンダーの市場ポジショニング
  • Amryt Pharma
  • Fresenius
  • Johnson & Johnson
  • Novartis
  • Pfizer

第13章 付録

  • 調査方法
  • 略語のリスト
目次
Product Code: IRTNTR30680

About this market

Despite the significant research activities undertaken over the past several decades, a promising treatment with very few side effects is not yet developed for the treatment of epidermolysis bullosa. Hence, various government and private organizations are releasing funds to advance the research on the development of promising therapeutics that can demonstrate better safety and efficacy than the available medications for the treatment of epidermolysis bullosa. The funding for the research on epidermolysis bullosa in Europe is also increasing. Such funding and financial supports are helpful for the development of novel therapeutic drugs for the treatment of epidermolysis bullosa. Technavio's analysts have predicted that the epidermolysis bullosa therapeutics market will register a CAGR of almost 5% by 2023.

Market Overview

Rising awareness about epidermolysis bullosa

Epidermolysis bullosa is a group of inherited diseases in which the skin becomes very brittle and forms acute blisters after a minor injury or gentle friction. Therefore, to avoid the delay in the diagnosis and the unawareness of the treatment options, several government and non-government organizations are conducting various awareness programs.

Lack of approved therapeutics

The unavailability of approved therapeutics for the treatment of epidermolysis bullosa is expected to hamper the growth of the epidermolysis bullosa therapeutics market over the forecast period.

For the detailed list of factors that will drive and challenge the growth of the epidermolysis bullosa therapeutics market during the 2019-2023, view our report.view our report.

Competitive Landscape

The market appears to be fragmented and with the presence of several companies. This market research report will help clients identify new growth opportunities and design unique growth strategies by providing a comprehensive analysis of the market's competitive landscape and offering information on the products offered by companies.

TABLE OF CONTENTS

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

  • 2.1 Preface
  • 2.2 Preface
  • 2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

  • Market ecosystem
  • Market characteristics
  • Market segmentation analysis

PART 04: MARKET SIZING

  • Market definition
  • Market sizing 2018
  • Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

PART 06: MARKET SEGMENTATION BY PRODUCT

  • Market segmentation by product
  • Comparison by product
  • Antibiotics - Market size and forecast 2018-2023
  • Analgesics - Market size and forecast 2018-2023
  • Other therapeutics - Market size and forecast 2018-2023
  • Market opportunity by product

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2018-2023
  • Europe - Market size and forecast 2018-2023
  • Asia - Market size and forecast 2018-2023
  • ROW - Market size and forecast 2018-2023
  • Key leading countries
  • Market opportunity

PART 09: DRIVERS AND CHALLENGES

  • Market drivers
  • Market challenges

PART 10: MARKET TRENDS

PART 11: VENDOR LANDSCAPE

  • Overview
  • Landscape disruption
  • Competitive scenario

PART 12: VENDOR ANALYSIS

  • Vendors covered
  • Vendor classification
  • Market positioning of vendors
  • Amryt Pharma
  • Fresenius
  • Johnson & Johnson
  • Novartis
  • Pfizer

PART 13: APPENDIX

  • Research methodology
  • List of abbreviations

List of Exhibits

  • Exhibit 01: Years in consideration
  • Exhibit 02: Global rare diseases therapeutics market
  • Exhibit 03: Segments of global rare diseases therapeutics market
  • Exhibit 04: Market characteristics
  • Exhibit 05: Market definition - Inclusions and exclusions checklist
  • Exhibit 06: Market size 2018
  • Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)
  • Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)
  • Exhibit 09: Five forces analysis 2018
  • Exhibit 10: Five forces analysis 2023
  • Exhibit 11: Bargaining power of buyers
  • Exhibit 12: Bargaining power of suppliers
  • Exhibit 13: Threat of new entrants
  • Exhibit 14: Threat of substitutes
  • Exhibit 15: Threat of rivalry
  • Exhibit 16: Market condition - Five forces 2018
  • Exhibit 17: Product - Market share 2018-2023 (%)
  • Exhibit 18: Comparison by product
  • Exhibit 19: Antibiotics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 20: Antibiotics - Year-over-year growth 2019-2023 (%)
  • Exhibit 21: Analgesics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 22: Analgesics - Year-over-year growth 2019-2023 (%)
  • Exhibit 23: Other therapeutics - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 24: Other therapeutics - Year-over-year growth 2019-2023 (%)
  • Exhibit 25: Market opportunity by product
  • Exhibit 26: Customer landscape
  • Exhibit 27: Market share by geography 2018-2023 (%)
  • Exhibit 28: Geographic comparison
  • Exhibit 29: North America - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 30: North America - Year-over-year growth 2019-2023 (%)
  • Exhibit 31: Top 3 countries in North America
  • Exhibit 32: Europe - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 33: Europe - Year-over-year growth 2019-2023 (%)
  • Exhibit 34: Top 3 countries in Europe
  • Exhibit 35: Asia - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 36: Asia - Year-over-year growth 2019-2023 (%)
  • Exhibit 37: Top 3 countries in Asia
  • Exhibit 38: ROW - Market size and forecast 2018-2023 ($ millions)
  • Exhibit 39: ROW - Year-over-year growth 2019-2023 (%)
  • Exhibit 40: Top 3 countries in ROW
  • Exhibit 41: Key leading countries
  • Exhibit 42: Market opportunity
  • Exhibit 43: Decision framework
  • Exhibit 44: Recent therapeutics that have received orphan drug designation from the US FDA
  • Exhibit 45: Impact of drivers and challenges
  • Exhibit 46: Early phase developmental therapeutics for the treatment of epidermolysis bullosa
  • Exhibit 47: Vendor landscape
  • Exhibit 48: Landscape disruption
  • Exhibit 49: Vendors covered
  • Exhibit 50: Vendor classification
  • Exhibit 51: Market positioning of vendors
  • Exhibit 52: Amryt Pharma - Vendor overview
  • Exhibit 53: Amryt Pharma - Business segments
  • Exhibit 54: Amryt Pharma - Organizational developments
  • Exhibit 55: Amryt Pharma - Geographic focus
  • Exhibit 56: Amryt Pharma - Segment focus
  • Exhibit 57: Amryt Pharma - Key offerings
  • Exhibit 58: Amryt Pharma - Key customers
  • Exhibit 59: Fresenius - Vendor overview
  • Exhibit 60: Fresenius - Business segments
  • Exhibit 61: Fresenius - Organizational developments
  • Exhibit 62: Fresenius - Geographic focus
  • Exhibit 63: Fresenius - Segment focus
  • Exhibit 64: Fresenius - Key offerings
  • Exhibit 65: Fresenius - Key customers
  • Exhibit 66: Johnson & Johnson - Vendor overview
  • Exhibit 67: Johnson & Johnson - Business segments
  • Exhibit 68: Johnson & Johnson - Organizational developments
  • Exhibit 69: Johnson & Johnson - Geographic focus
  • Exhibit 70: Johnson & Johnson - Segment focus
  • Exhibit 71: Johnson & Johnson - Key offerings
  • Exhibit 72: Johnson & Johnson - Key customers
  • Exhibit 73: Novartis - Vendor overview
  • Exhibit 74: Novartis - Business segments
  • Exhibit 75: Novartis - Organizational developments
  • Exhibit 76: Novartis - Geographic focus
  • Exhibit 77: Novartis - Segment focus
  • Exhibit 78: Novartis - Key offerings
  • Exhibit 79: Novartis - Key customers
  • Exhibit 80: Pfizer - Vendor overview
  • Exhibit 81: Pfizer - Business segments
  • Exhibit 82: Pfizer - Organizational developments
  • Exhibit 83: Pfizer - Geographic focus
  • Exhibit 84: Pfizer - Segment focus
  • Exhibit 85: Pfizer - Key offerings
  • Exhibit 86: Pfizer - Key customers
  • Exhibit 87: Validation techniques employed for market sizing
  • Exhibit 88: List of abbreviations